In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1366-1376

  Callebaut, Christian ^a   Stray, Kirsten ^a   Tsai, Luong ^a   Williams, Matt ^a   Yang, Zheng Yu ^a   Cannizzaro, Carina ^a   Leavitt, Stephanie A ^a   Liu, Xiaohong ^a   Wang, Kelly ^a   Murray, Bernard P ^a   Mulato, Andrew ^a   Hatada, Marcos ^a   Priskich, Tina ^b   Parkin, Neil ^b,c   Swaminathan, Swami ^a   Lee, William ^a   He, Gong Xin ^a   Xu, Lianhong ^a   Cihlar, Tomas ^a  

^a GILEAD SCIENCES   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

^c DATA FIRST CONSULTING INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; BRECANAVIR; DARUNAVIR; EFAVIRENZ PLUS TENOFOVIR; ELVITEGRAVIR; EMTRICITABINE; ETRAVIRINE; GS 8374; HEXAHYDROFURO[2,3 B]FURAN 3 YL 1 [4 [(DIETHOXYPHOSPHORYL)METHOXY]PHENYL] 3 HYDROXY 4 (N ISOBUTYL 4 METHOXYPHENYLSULFONAMIDO)BUTAN 2 YLCARBAMATE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LOPINAVIR; NELFINAVIR; PHOSPHONIC ACID DERIVATIVE; PROTEINASE; PROTEINASE INHIBITOR; RIBAVIRIN PLUS STAVUDINE; RILPIVIRINE; RITONAVIR; SAQUINAVIR; TENOFOVIR; TIPRANAVIR; TMC 126; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL TYPE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG DETERMINATION; DRUG ISOLATION; DRUG POTENCY; DRUG POTENTIATION; ENTHALPY; ENTROPY; ENZYME BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; ISOTHERMAL TITRATION CALORIMETRY; LIVER MICROSOME METABOLISM; MACROPHAGE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; T LYMPHOCYTE; THERMODYNAMICS; VIRUS RESISTANCE;

CALORIMETRY; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CRYSTALLOGRAPHY, X-RAY; HEK293 CELLS; HEP G2 CELLS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MOLECULAR STRUCTURE; PHOSPHONIC ACIDS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 79953216020     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01183-10     Document Type: Article

References (53)

1. Bartlett, J. A., R. DeMasi, J. Quinn, C. Moxham, and F. Rousseau. 2001. Overview of the effectiveness of triple combination therapy in antiretroviralnaive HIV-1 infected adults. AIDS 15:1369-1377. (Pubitemid 32663904)
2. Callebaut, C., et al. 2007. In vitro HIV-1 resistance selection to GS-8374, a novel phosphonate protease inhibitor: comparison with lopinavir, atazanavir, and darunavir, abstr. 16. Abstr. 16th Int. HIV Drug Resistance Workshop.
3. Carr, A. 2003. Toxicity of antiretroviral therapy and implications for drug development. Nat. Rev. Drug Discov. 2:624-634.
4. Cihlar, T., et al. 2006. Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring. J. Mol. Biol. 363:635-647.
5. Clotet, B., et al. 2007. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369:1169-1178. (Pubitemid 46541620)
6. De Meyer, S., et al. 2005. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49:2314-2321.
7. Detels, R., et al. 1998. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 280:1497-1503. (Pubitemid 28507402)
8. DHHS, Office of AIDS Research Advisory Council. 2009. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. DHHS, Office of AIDS Research Advisory Council, Washington, DC.
9. Ghosh, A. K., B. D. Chapsal, I. T. Weber, and H. Mitsuya. 2008. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. Acc. Chem. Res. 41:78-86.
10. Ghosh, A. K., E. Pretzer, H. Cho, K. A. Hussain, and N. Duzgunes. 2002. Antiviral activity of UIC-PI, a novel inhibitor of the human immunodeficiency virus type 1 protease. Antiviral Res. 54:29-36. (Pubitemid 34219172)
11. Hazen, R., et al. 2007. In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. Antimicrob. Agents Chemother. 51:3147-3154.
12. Hruz, P., et al. 2011. GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system. Antimicrob. Agents Chemother. 55:1377-1382.
13. Imaz, A., et al. 2009. Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. J. Acquir. Immune Defic. Syndr. 52:382-386.
14. Johnson, V. A., et al. 2009. Update of the drug resistance mutations in HIV-1: December 2009. Top. HIV Med. 17:138-145.
15. Kirk, J. B., and M. B. Goetz. 2009. Human immunodeficiency virus in an aging population, a complication of success. J. Am. Geriatr. Soc. 57:2129-2138.
16. Ledford, R., N. Margot, M. Miller, and D. McColl. 2007. Elvitegravir (GS-9137/JTK-303), an HIV-1 integrase inhibitor, has additive to synergistic interactions with antiretroviral drugs in vitro, abstr. 052. Abstr. 4th Int. AIDS Soc. Conf. HIV Pathogenesis, Treatment, Prevention.
17. Little, S. J., et al. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-394.
18. Lucia, M. B., et al. 2005. Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. J. Acquir. Immune Defic. Syndr. 39:635-637.
19. Madruga, J. V., et al. 2007. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 370:49-58. (Pubitemid 47023100)
20. Markgren, P. O., et al. 2001. Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology. Anal. Biochem. 291:207-218.
21. Miller, J. F., et al. 2006. Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. Bioorg. Med. Chem. Lett. 16:1788-1794.
22. Miller, J. F., et al. 2005. Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles. Bioorg. Med. Chem. Lett. 15:3496-3500.
23. Mills, A. M., et al. 2009. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 23:1679-1688.
24. Morse, G. D., L. M. Catanzaro, and E. P. Acosta. 2006. Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy. Lancet Infect. Dis. 6:215-225.
25. Murphy, E. L., et al. 2001. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann. Intern. Med. 135:17-26.
26. Nijhuis, M., et al. 2007. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med. 4:e36.
27. Nolan, D. 2003. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 63:2555-2574. (Pubitemid 37491560)
28. Obach, R. S. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro halflife approach and nonspecific binding to microsomes. Drug Metab. Dispos. 27:1350-1359.
29. Palella, F. J., Jr., et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338:853-860.
30. Parker, R. A., et al. 2005. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol. Pharmacol. 67:1909-1919.
31. Parkin, N., C. Chappey, E. Lam, and C. J. Petropoulos. 2005. Reduced susceptibility to protease inhibitors (PI) in the absence of primary PI resistance-associated mutations, abstr. H-1062. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
32. Petropoulos, C. J., et al. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
33. Prichard, M., K. Aseltine, and C. Shipman, Jr. 1993. MacSynergy II, 1.0 ed. University of Michigan, Ann Arbor, MI.
34. Prichard, M. N., L. E. Prichard, and C. Shipman, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob. Agents Chemother. 37:540-545.
35. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14:181-205. (Pubitemid 20377558)
36. Richman, D. D., et al. 2004. The prevalence of antiretroviral drug resistance in the United States. AIDS 18:1393-1401. (Pubitemid 38925131)
37. Robinson, B. S., et al. 2000. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 44:2093-2099.
38. Sax, P. E., and P. Kumar. 2004. Tolerability and safety of HIV protease inhibitors in adults. J. Acquir. Immune Defic. Syndr. 37:1111-1124.
39. Sigurskjold, B. W. 2000. Exact analysis of competition ligand binding by displacement isothermal titration calorimetry. Anal. Biochem. 277:260-266.
40. Spaltenstein, A., W. M. Kazmierski, J. F. Miller, and V. Samano. 2005. Discovery of next generation inhibitors of HIV protease. Curr. Top. Med. Chem. 5:1589-1607.
41. Storch, C. H., D. Theile, H. Lindenmaier, W. E. Haefeli, and J. Weiss. 2007. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem. Pharmacol. 73:1573-1581.
42. Surleraux, D. L., et al. 2005. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J. Med. Chem. 48:1813-1822.
43. Swanstrom, R., and J. Erona. 2000. Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance. Pharmacol. Ther. 86:145-170.
44. Tamalet, C., J. Fantini, C. Tourres, and N. Yahi. 2003. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS 17:2383-2388.
45. Velazquez-Campoy, A., Y. Kiso, and E. Freire. 2001. The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. Arch. Biochem. Biophys. 390:169-175.
46. Vittinghoff, E., et al. 1999. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J. Infect. Dis. 179:717-720.
47. Wensing, A. M., and C. A. Boucher. 2003. Worldwide transmission of drug-resistant HIV. AIDS Rev. 5:140-155.
48. Wensing, A. M., N. M. van Maarseveen, and M. Nijhuis. 2010. Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res. 85:59-74.
49. Xu, L., and M. C. Desai. 2009. Pharmacokinetic enhancers for HIV drugs. Curr. Opin. Invest. Drugs 10:775-786.
50. Yazdanpanah, Y., et al. 2009. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin. Infect. Dis. 49:1441-1449.
51. Yoshimura, K., et al. 2002. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J. Virol. 76:1349-1358. (Pubitemid 34066437)
52. Yusa, K., and S. Harada. 2004. Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro. Curr. Pharm. Des. 10:4055-4064.
53. Zolopa, A. R. 2010. The evolution of HIV treatment guidelines: current state-of-the-art of ART. Antiviral Res. 85:241-244.